Skip to main content
SpringerLink
Log in

Ceftaroline fosamil: a guide to its use in complicated skin and soft tissue infections and community-acquired pneumonia in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Ceftaroline fosamil (Zinforo™; Teflaro®), the prodrug of ceftaroline, is an advanced-generation, parenteral cephalosporin with a broad spectrum of activity against clinically relevant Gram-positive and Gram-negative organisms. In clinical trials, intravenous ceftaroline fosamil was an effective and generally well tolerated treatment in hospitalized patients with complicated skin and soft tissue infections (noninferior to intravenous vancomycin plus aztreonam) or hospitalized community-acquired pneumonia (superior to intravenous ceftriaxone).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lodise T, Low DE. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs. 2012;72(11):1473–93.

    Article  CAS  PubMed  Google Scholar 

  2. Casapao AM, Steed ME, Levine DP, et al. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opin Pharmacother. 2012;13(8):1177–86.

    Article  CAS  PubMed  Google Scholar 

  3. Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009;69(7):809–31.

    Article  CAS  PubMed  Google Scholar 

  4. Viasus D, Garcia-Vidal C, Carratalà J. Advances in antibiotic therapy for community-acquired pneumonia. Curr Opin Pulm Med. 2013;19(3):209–15.

    Article  CAS  PubMed  Google Scholar 

  5. Aliberti S, Kaye KS. The changing microbiologic epidemiology of community-acquired pneumonia. Postgrad Med. 2013;125(6):31–42.

    Article  PubMed  Google Scholar 

  6. Frampton JE. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs. 2013;73(10):1067–94.

    Article  CAS  PubMed  Google Scholar 

  7. Barbour A, Schmidt S, Rand KH, et al. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimcrob Agents. 2009;34(1):1–7.

    Article  CAS  Google Scholar 

  8. Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009;11(4):282–6.

    PubMed  Google Scholar 

  9. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(Suppl 3):iii11–8.

  10. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54(5):1670–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65(4):713–6.

    Article  CAS  PubMed  Google Scholar 

  12. Teflaro® (ceftaroline fosamil) injection for intravenous (IV) use: US prescribing information. St. Louis: Forest Pharmaceuticals, Inc.; 2013.

  13. Zinforo 600 mg powder for concentrate for solution for infusion: summary of product characteristics. London: European Medicines Agency; 2014.

  14. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv41–51.

  15. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv53–65.

  16. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–50.

    Article  CAS  PubMed  Google Scholar 

  17. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii19–32.

    CAS  PubMed  Google Scholar 

  18. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii33–44.

    CAS  PubMed  Google Scholar 

  19. Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind phase 3 noninferiority with nested superiority trial. Lancet Infect Dis. (In press).

  20. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395–405.

    Article  CAS  PubMed  Google Scholar 

  21. Taboada M, Melnick D, Iaconis J, et al. Antecedent antibiotic therapy decreases effect size in community-acquired pneumonia (CAP) therapy trials: meta-analysis of randomized trials of ceftaroline fosamil vs ceftriaxone [poster no. L-1748a]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5–9 Sep 2014; Washington (DC).

  22. Ramani A, Udeani G, Evans J, et al. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. J Chemother. 2014;26(4):229–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Santos PD, Davis A, Jandourek A, et al. Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. J Chemother. 2013;25(6):341–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58(5):2541–6.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv67–71.

  26. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii53–9.

  27. File TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(Suppl 3):S173–80.

    Article  CAS  PubMed  Google Scholar 

  28. Panagiotidis G, Backstrom T, Asker-Hagelberg C, et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010;54(5):1811–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics. 2007;25(9):751–68.

    Article  PubMed  Google Scholar 

  30. Lode HM. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin Microbiol Infect. 2009;15(3):212–7.

    Article  CAS  PubMed  Google Scholar 

  31. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.

    Article  PubMed  Google Scholar 

  32. Nathwani D, Morgan M, Masterton R, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61(5):976–94.

    Article  CAS  PubMed  Google Scholar 

  33. Moellering RC, Jr. The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother. 2010;65 Suppl 4:iv3–8.

  34. Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother. 2010;65:24–36.

    Article  CAS  PubMed  Google Scholar 

  35. Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care. 2009;15(5):403–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: H. S. Sader, Surveillance JMI Laboratories, North Liberty, IA, USA; S. Saluja, Saran Ashram, Agra, India; R. B. Shah, Gujarat Medical Education and Research Society Medical College, Department of Pharmacology, Gandhinagar, Gujarat, India.

Disclosure

This article was updated from Drugs 2013; 73; 1067–94 [6] by salaried employees of Adis/Springer. The preparation of these reviews was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Lesley J. Scott & James E. Frampton

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J., Frampton, J.E. Ceftaroline fosamil: a guide to its use in complicated skin and soft tissue infections and community-acquired pneumonia in the EU. Drugs Ther Perspect 31, 9–16 (2015). https://doi.org/10.1007/s40267-014-0174-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-014-0174-9

Keywords

Search

Navigation